Reports Q1 revenue $3.3M, consensus $3.05M. “We have kicked off 2024 strong. I am pleased with our commercial progress shown by sales across US and international accounts, as well as the important milestones we hit in Q1 by commencing CARE PMR study enrollment in Alzheimer’s and launching our 8th generation AI-powered software,” said Maria Sainz, Chief Executive Officer and President of Hyperfine, Inc. “Commercialization, Clinical Evidence, and Innovation remain our three value drivers. In Q1, we demonstrated that our team is capable of delivering on all three and doing so with strong spending discipline.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HYPR:
- HYPR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Hyperfine enters European distribution deals for Swoop system
- Hyperfine reports 1st AD patients enrolled in CARE PMR observational study
- SEC Baby Shelf Rules Stunt Hyperfine Inc.’s Fundraising Flexibility
- Hyperfine price target lowered to $1.30 from $1.70 at B. Riley